Soluble MHC-peptide complexes: Tools for the monitoring of T cell responses in clinical trials and basic research

Cancer Immunity

Volumn 9, Issue , 2009, Pages

  Guillaume, Philippe ^a   Dojcinovic, Danijel ^a   Luescher, Immanuel F ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Human; Immunologic monitoring; MHC peptide complex; Mouse; Tetramer

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TETRAMER;

ANIMAL CELL; ANTIGEN SPECIFICITY; CANCER IMMUNOLOGY; CANCER RESEARCH; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HLA SYSTEM; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; NOTE; QUANTITATIVE ANALYSIS; STAINING; T LYMPHOCYTE;

EID: 74749107592     PISSN: None     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Note

References (56)

1. Chattopadhyay PK, Melenhorst JJ, Ladell K, Gostick E, Scheinberg P, Barrett AJ, Wooldridge L, Roederer M, Sewell AK, Price DA. Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramers. Cytometry 2008; 73: 1001-1009. (PMID: 18836993)
2. Bakker AH, Schumacher TN. MHC multimer technology: current status and future prospects. Curr Opin Immunol 2005; 17: 428-433. (PMID: 15967654)
3. Wooldridge L, Lissina A, Cole DK, van den Berg HA, Price DA, Sewell AK. Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology 2009; 126: 147-164. (PMID: 19125886)
4. Vollers SS, Stern LJ. Class II major histocompatibility complex tetramer staining: progress, problems, and prospects. Immunology 2008; 123: 305-313. (PMID: 18251991)
5. James EA, LaFond R, Durinovic-Bello I, Kwok W. Visualizing antigen specific CD4+ T cells using MHC class II tetramers. J Vis Exp 2009; (25): pii: 1167. doi: 10.3791/1167. (PMID: 19270641)
6. Scriba TJ, Purbhoo M, Day CL, Robinson N, Fidler S, Fox J, Weber JN, Klenerman P, Sewell AK, Phillips RE. Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. J Immunol 2005; 175: 6334-6343. (PMID: 16272285)
7. Lissina A, Ladell K, Skowera A, Clement M, Edwards E, Seggewiss R, van den Berg HA, Gostick E, Gallagher K, Jones E, Melenhorst JJ, Godkin AJ, Peakman M, Price DA, Sewell AK, Wooldridge L. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods 2009; 340: 11-24. (PMID: 18929568)
8. Melenhorst JJ, Scheinberg P, Chattopadhyay PK, Lissina A, Gostick E, Cole DK, Wooldridge L, van den Berg HA, Bornstein E, Hensel NF, Douek DC, Roederer M, Sewell AK, Barrett AJ, Price DA. Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. J Immunol Methods 2008; 338: 31-39. (PMID: 18675271)
9. Dimopoulos N, Jackson HM, Ebert L, Guillaume P, Luescher IF, Ritter G, Chen W. Combining MHC tetramer and intracellular cytokine staining for CD8(+) T cells to reveal antigenic epitopes naturally presented on tumor cells. J Immunol Methods 2009; 340: 90-94. (PMID: 18957296)
10. LICR Tetramer Collection. URL: http://www.cancerimmunity.org/ tetramers/
11. Guillaume P, Legler DF, Boucheron N, Doucey MA, Cerottini JC, Luescher IF. Soluble major histocompatibility complex-peptide octamers with impaired CD8 binding selectively induce Fas-dependent apoptosis. J Biol Chem 2003; 278: 4500-4509. (PMID: 12407102)
12. Neveu B, Echasserieau K, Hill T, Kuus-Reichel K, Houssaint E, Bonneville M, Saulquin X. Impact of CD8-MHC class I interaction in detection and sorting efficiencies of antigen-specific T cells using MHC class I/peptide multimers: contribution of pMHC valency. Int Immunol 2006; 18: 1139-1145. (PMID: 16751231)
13. Moody AM, Chui D, Reche PA, Priatel JJ, Marth JD, Reinherz EL. Developmentally regulated glycosylation of the CD8alphabeta coreceptor stalk modulates ligand binding. Cell 2001; 107: 501-512. (PMID: 11719190)
14. Bosselut R, Kubo S, Guinter T, Kopacz JL, Altman JD, Feigenbaum L, Singer A. Role of CD8beta domains in CD8 coreceptor function: importance for MHC I binding, signaling, and positive selection of CD8+ T cells in the thymus. Immunity 2000; 12: 409-418. (PMID: 10795739)
15. Hernández J, Lee PP, Davis MM, Sherman LA. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J Immunol 2000; 164: 596-602. (PMID: 10623800)
16. Cebecauer M, Guillaume P, Hozák P, Mark S, Everett H, Schneider P, Luescher IF. Soluble MHC-peptide complexes induce rapid death of CD8+ CTL. J Immunol 2005; 174: 6809-6819. (PMID: 15905522)
17. Xu XN, Purbhoo MA, Chen N, Mongkolsapaya J, Cox JH, Meier UC, Tafuro S, Dunbar PR, Sewell AK, Hourigan CS, Appay V, Cerundolo V, Burrows SR, McMichael AJ, Screaton GR. A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity 2001; 14: 591-602. (PMID: 11371361)
18. Guillaume P, Baumgaertner P, Angelov GS, Speiser D, Luescher IF. Fluorescence-activated cell sorting and cloning of bona fide CD8+ CTL with reversible MHC-peptide and antibody Fab' conjugates. J Immunol 2006; 177: 3903-3912. (PMID: 16951353)
19. Luescher IF, Vivier E, Layer A, Mahiou J, Godeau F, Malissen B, Romero P. CD8 modulation of T-cell antigen receptor-ligand interactions on living cytotoxic T lymphocytes. Nature 1995; 373: 353-356. (PMID: 7830771)
20. Guillaume P, Baumgaertner P, Neff L, Rufer N, Speiser DE, Luescher IF. Novel soluble HLA-A2/Melan-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in melanoma patients. Int J Cancer 2009; in press.
21. De Vries IJ, Bernsen MR, van Geloof WL, Scharenborg NM, Lesterhuis WJ, Rombout PD, Van Muijen GN, Figdor CG, Punt CJ, Ruiter DJ, Adema GJ. In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients. Cancer Immunol Immunother 2007; 56: 1667-1676. (PMID: 17440724)
22. Demotte N, Stroobant V, Courtoy PJ, Van Der Smissen P, Colau D, Luescher IF, Hivroz C, Nicaise J, Squifflet JL, Mourad M, Godelaine D, Boon T, van der Bruggen P. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 2008; 28: 414-424. (PMID: 18342010)
23. Drake DR 3rd, Ream RM, Lawrence CW, Braciale TJ. Transient loss of MHC class I tetramer binding after CD8+ T cell activation reflects altered T cell effector function. J Immunol 2005; 175: 1507-1515. (PMID: 16034088)
24. Kao C, Daniels MA, Jameson SC. Loss of CD8 and TCR binding to Class I MHC ligands following T cell activation. Int Immunol 2005; 17: 1607-1617. (PMID: 16263755)
25. Comelli EM, Sutton-Smith M, Yan Q, Amado M, Panico M, Gilmartin T, Whisenant T, Lanigan CM, Head SR, Goldberg D, Morris HR, Dell A, Paulson JC. Activation of murine CD4+ and CD8+ T lymphocytes leads to dramatic remodeling of N-linked glycans. J Immunol 2006; 177: 2431-2440. (PMID: 16888005)
26. Garner OB, Baum LG. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. Biochem Soc Trans 2008; 36: 1472-1477. (PMID: 19021578)
27. Chen IJ, Chen HL, Demetriou M. Lateral compartmentalization of T cell receptor versus CD45 by galectin-N-glycan binding and microfilaments coordinate basal and activation signaling. J Biol Chem 2007; 282: 35361-35372. (PMID: 17897956)
28. Wooldridge L, Scriba TJ, Milicic A, Laugel B, Gostick E, Price DA, Phillips RE, Sewell AK. Anti-coreceptor antibodies profoundly affect staining with peptide-MHC class I and class II tetramers. Eur J Immunol 2006; 36: 1847-1855. (PMID: 16783852)
29. Appay V, Rowland-Jones SL. The assessment of antigen-specific CD8+ T cells through the combination of MHC class I tetramer and intracellular staining. J Immunol Methods 2002; 268: 9-19. (PMID: 12213338)
30. Cameron TO, Cochran JR, Yassine-Diab B, Sékaly RP, Stern LJ. Cutting edge: detection of antigen-specific CD4+ T cells by HLADR1 oligomers is dependent on the T cell activation state. J Immunol 2001; 166: 741-745. (PMID: 11145645)
31. Hampl J, Chien YH, Davis MM. CD4 augments the response of a T cell to agonist but not to antagonist ligands. Immunity 1997; 7: 379-385. (PMID: 9324358)
32. Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P; HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 2009; 58: 1701-1713. (PMID: 19259668)
33. Keilholz U, Martus P, Scheibenbogen C. Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res 2006; 12: 2346s-2352s. (PMID: 16609057)
34. Tomiyama H, Takata H, Matsuda T, Takiguchi M. Phenotypic classification of human CD8+ T cells reflecting their function: inverse correlation between quantitative expression of CD27 and cytotoxic effector function. Eur J Immunol 2004; 34: 999-1010. (PMID: 15048710)
35. Walker EB, Miller W, Haley D, Floyd K, Curti B, Urba WJ. Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood. Clin Cancer Res 2009; 15: 2541-2551. (PMID: 19318471)
36. Speiser DE, Baumgaertner P, Barbey C, Rubio-Godoy V, Moulin A, Corthesy P, Devevre E, Dietrich PY, Rimoldi D, Liénard D, Cerottini JC, Romero P, Rufer N. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol 2006; 177: 1338-1348. (PMID: 16818795)
37. Xu Y, Theobald V, Sung C, DePalma K, Atwater L, Seiger K, Perricone MA, Richards SM. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients. J Transl Med 2008; 6: 61. (PMID: 18945350)
38. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, Förster R, Rowland-Jones S, Sékaly RP, McMichael AJ, Pantaleo G. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001; 410: 106-111. (PMID: 11242051)
39. Devêvre E, Romero P, Mahnke YD. LiveCount Assay: concomitant measurement of cytolytic activity and phenotypic characterisation of CD8(+) T-cells by flow cytometry. J Immunol Methods 2006; 311: 31-46. (PMID: 16527300)
40. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A; Elispot Proficiency Panel of the CVC Immune Assay Working Group. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 2008; 57: 303-315. (PMID: 17721781)
41. Speiser DE, Pittet MJ, Guillaume P, Lubenow N, Hoffman E, Cerottini JC, Romero P. Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J Immunother 2004; 27: 298-308. (PMID: 15235391)
42. Anichini A, Vegetti C, Mortarini R. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol. Immunother 2004; 53: 855-864. (PMID: 15175905)
43. Richmond A, Yang J, Su Y. The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res 2009; 22: 175-186. (PMID: 19222802)
44. Gao JQ, Okada N, Mayumi T, Nakagawa S. Immune cell recruitment and cell-based system for cancer therapy. Pharm Res 2008; 25: 752-768. (PMID: 17891483)
45. Müller G, Höpken UE, Stein H, Lipp M. Systemic immunoregulatory and pathogenic functions of homeostatic chemokine receptors. J Leukoc Biol 2002; 72: 1-8. (PMID: 12101256)
46. Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, Eberlein TJ, Hsieh CS, Linehan DC. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 2009; 182: 1746-1755. (PMID: 19155524)
47. Ishida T, Ueda R. CCR4 as a novel molecular target for immuno- therapy of cancer. Cancer Sci 2006; 97: 1139-1146. (PMID: 16952304)
48. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69: 3077-3085. (PMID: 19293190)
49. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998; 161: 927-932. (PMID: 9670971)
50. Musha H, Ohtani H, Mizoi T, Kinouchi M, Nakayama T, Shiiba K, Miyagawa K, Nagura H, Yoshie O, Sasaki I. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer 2005; 116: 949-956. (PMID: 15856455)
51. Hyakudomi M, Matsubara T, Hyakudomi R, Yamamoto T, Kinugasa S, Yamanoi A, Maruyama R, Tanaka T. Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol 2008; 15: 1775-1782. (PMID: 18363071)
52. Tang L, Hu HD, Hu P, Lan YH, Peng ML, Chen M, Ren H. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther 2007; 14: 1226-1234. (PMID: 17597794)
53. Andersson A, Yang SC, Huang M, Zhu L, Kar UK, Batra RK, Elashoff D, Strieter RM, Dubinett SM, Sharma S. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol 2009; 182: 6951-6958. (PMID: 19454692)
54. Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Haas I, Mackensen A, Køllgaard T, thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanovic S, Wölfel T, van der Burg SH. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of anti-gen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 2008; 57: 289-302. (PMID: 17721783)
55. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB. Immuno-logic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. Immunother 2002; 25: 97-138. (PMID: 12074049)
56. Heijnen IA, Barnett D, Arroz MJ, Barry SM, Bonneville M, Brando B, D'hautcourt JL, Kern F, Tötterman TH, Marijt EW, Bossy D, Preijers FW, Rothe G, Gratama JW; European Working Group on Clinical Cell Analysis. Enumeration of antigen-specific CD8+ T lymphocytes by single-platform, HLA tetramer-based flow cytometry: a European multicenter evaluation. Cytometry B Clin Cytom 2004; 62: 1-13. (PMID: 15468327)